News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
323 Results
Type
Article (10)
Company Profile (1)
Press Release (312)
Section
Business (60)
Deals (11)
Drug Development (109)
FDA (6)
Job Trends (3)
News (195)
Policy (26)
Tag
Alliances (16)
Antibody-drug conjugate (ADC) (3)
Approvals (6)
Artificial intelligence (1)
Best Places to Work (1)
Biotechnology (1)
Cancer (2)
Cell therapy (2)
Clinical research (94)
Collaboration (1)
Data (1)
Diagnostics (1)
Earnings (24)
Editorial (1)
Events (33)
Executive appointments (1)
FDA (8)
Funding (2)
Gene therapy (1)
IPO (5)
Job creations (2)
Legal (1)
Manufacturing (1)
Mergers & acquisitions (6)
Metabolic disorders (1)
NextGen: Class of 2026 (2)
Obesity (1)
Ovarian cancer (2)
People (18)
Phase 1 (10)
Phase 2 (50)
Phase 3 (37)
Pipeline (1)
Postmarket research (3)
Preclinical (9)
Radiopharmaceuticals (1)
Rare diseases (1)
Regulatory (28)
Series A (1)
Series B (1)
Startups (4)
Vaccines (3)
Date
Last 365 days (9)
2026 (1)
2025 (9)
2024 (14)
2023 (8)
2022 (5)
2021 (4)
2020 (9)
2019 (7)
2018 (7)
2017 (22)
2016 (18)
2015 (24)
2014 (24)
2013 (38)
2012 (35)
2011 (31)
2010 (27)
Location
Asia (12)
Australia (3)
California (2)
China (1)
Europe (24)
Massachusetts (1)
Nevada (1)
New Jersey (3)
Pennsylvania (1)
South America (1)
Southern California (2)
United States (7)
323 Results for "oncusp therapeutics.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
OnCusp Therapeutics Appoints Dimitry Nuyten, M.D., Ph.D., as Chief Medical Officer
June 23, 2025
·
4 min read
ADC-Focused OnCusp Therapeutics Emerges with $100M Series A Raise
Targeting the red hot antibody-drug conjugate market, OnCusp Therapeutics is coming out of the gate with $100 million from investors such as Novo Holdings and OrbiMed.
January 5, 2024
·
2 min read
·
Tyler Patchen
Press Releases
OnCusp Therapeutics Receives FDA Fast Track Designation for CUSP06 for the Treatment of Platinum-Resistant Ovarian Cancer
February 13, 2025
·
4 min read
Pharm Country
OnCusp Therapeutics Raises Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients
OnCusp Therapeutics, Inc. today announced an oversubscribed $100 million Series A financing round.
January 4, 2024
·
4 min read
Press Releases
OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors at the 2025 ASCO Annual Meeting
June 3, 2025
·
5 min read
Drug Development
OnCusp Therapeutics Announces First Patient Dosed in Phase 1 Trial of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
OnCusp Therapeutics, Inc. today announced that the first patient has been dosed in the Phase 1 study evaluating CUSP06 for the treatment of platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
March 6, 2024
·
3 min read
Drug Development
OnCusp Therapeutics Receives FDA Clearance for the Phase 1 Clinical Trial of CUSP06, Targeting Ovarian Cancer and Other Advanced Solid Tumors
OnCusp Therapeutics announced today the clearance of its Investigational New Drug (IND) Application for CUSP06 by the U.S. Food and Drug Administration (FDA).
August 15, 2023
·
2 min read
OnCusp Therapeutics Showcases Potent Anti-Tumor Activity of its CDH6 ADC at AACR Annual Meeting 2023
OnCusp Therapeutics today announced that the preclinical data on its lead program CUSP06 will be presented during the American Association for Cancer Research Meeting.
April 11, 2023
·
2 min read
Business
OnCusp Therapeutics Commences Operations to Advance Innovative Oncology Therapies
OnCusp Therapeutics (or “OnCusp”), announced that it has officially commenced operations both in New York and Shanghai.
June 29, 2021
·
6 min read
Business
OnCusp Therapeutics and Multitude Therapeutics Enter into an Ex-China Licensing Agreement for a Potentially Highly Differentiated CDH6-Targeting Antibody Drug Conjugate
OnCusp Therapeutics announced today a licensing agreement with Multitude Therapeutics for the development and commercialization of AMT-707 (now referred to as CUSP06), a potentially highly differentiated second-in-class CDH6 antibody drug conjugate (“ADC”).
June 8, 2022
·
4 min read
1 of 33
Next
